What is the evidence for the use of GnRH analogues for more than 6 months in treating endometriosis or uterine fibroids?

This review examines the clinical evidence regarding the extended use of gonadotropin-releasing hormone analogues beyond the standard six-month duration for managing endometriosis and uterine fibroids. The authors highlight that while short-term efficacy is well-established, prolonged therapy necessitates careful monitoring due to significant side effects, particularly concerning bone mineral density loss. To mitigate these risks, the paper discusses the potential utility of add-back therapies in allowing for safer long-term administration when clinically indicated. Relevance to endometriosis: listed as one indication for GnRH antagonists, though the paper's main focus is uterine fibroids.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works